{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:49:41Z","timestamp":1784771381940,"version":"3.55.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.canlet.2019.09.017","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T11:05:16Z","timestamp":1570187116000},"page":"35-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics"],"prefix":"10.1016","volume":"469","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-8682","authenticated-orcid":false,"given":"Yuchen","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri","family":"Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8040-9890","authenticated-orcid":false,"given":"Libo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.09.017_bib1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"J. Am. Med. Assoc."},{"issue":"2019","key":"10.1016\/j.canlet.2019.09.017_bib2","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2019.09.017_bib3","doi-asserted-by":"crossref","unstructured":"W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015, CA A Cancer J. Clin. 66 (n.d) 115\u2013132. doi:10.3322\/caac.21338.","DOI":"10.3322\/caac.21338"},{"key":"10.1016\/j.canlet.2019.09.017_bib4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib5","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2016","key":"10.1016\/j.canlet.2019.09.017_bib6","first-page":"1","article-title":"American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mce.2015.06.029","article-title":"Mouse models of thyroid cancer: a 2015 update","volume":"421","author":"Kirschner","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/gb-2011-12-1-101","article-title":"The similarity of gene expression between human and mouse tissues","volume":"12","author":"Dowell","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2019.09.017_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-018-0903-0","article-title":"Therapeutic advances in anaplastic thyroid cancer: a current perspective","volume":"17","author":"Saini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2018.11.026","article-title":"MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6","volume":"443","author":"Jia","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.09.017_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1089\/thy.2009.1609","article-title":"Lessons from mouse models of thyroid cancer","volume":"19","author":"Kim","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib12","doi-asserted-by":"crossref","first-page":"71696","DOI":"10.18632\/oncotarget.12322","article-title":"Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy","volume":"7","author":"Hiroshima","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archoto.2007.36","article-title":"An orthotopic model of papillary thyroid carcinoma in athymic nude mice","volume":"134","author":"Ahn","year":"2008","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.canlet.2019.09.017_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/thy.2015.0511","article-title":"High-frequency ultrasound-guided injection for the generation of a novel orthotopic mouse model of human thyroid carcinoma","volume":"26","author":"Greco","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/thy.2013.0149","article-title":"An in vivo mouse model of metastatic human thyroid cancer","volume":"24","author":"Zhang","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc.2016.140","article-title":"Interrogating open issues in cancer precision medicine with patient-derived xenografts","volume":"17","author":"Byrne","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.it.2018.07.001","article-title":"Humanized mice for the study of immuno-oncology","volume":"39","author":"De La Rochere","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2019.09.017_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.2013.0483","article-title":"The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma","volume":"24","author":"Vanden Borre","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1541-7786.MCR-18-1026","article-title":"Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET\/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers","volume":"17","author":"Schweppe","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2017.307","article-title":"The generation and application of patient-derived xenograft model for cancer research","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2019.09.017_bib21","series-title":"Tumor Biol., American Association for Cancer Research","article-title":"Abstract 1458: characterization of novel thyroid PDX models and their response to combination therapies","author":"Marlow","year":"2015"},{"key":"10.1016\/j.canlet.2019.09.017_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","article-title":"Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer","volume":"30","author":"Laheru","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.canlet.2019.09.017_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2017.04.020","article-title":"Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers","volume":"146","author":"Colon-Otero","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12967-016-0861-5","article-title":"Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer","volume":"14","author":"Owonikoko","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib25","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6442","article-title":"Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model","volume":"6","author":"Duquette","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib26","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1186\/s12885-018-4854-z","article-title":"SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2019.09.017_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/ERC-19-0107","article-title":"Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer","volume":"26","author":"Zhu","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13277-015-3816-1","article-title":"2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma","volume":"37","author":"Lin","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.canlet.2019.09.017_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jss.2013.06.017","article-title":"Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer","volume":"185","author":"Wunderlich","year":"2013","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib31","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1210\/jc.2017-01845","article-title":"Methodology, criteria, and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts","volume":"103","author":"Marlow","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib32","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-16-0399","article-title":"Animal models of medullary thyroid cancer: state of the art and view to the future","volume":"24","author":"Vitale","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib33","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1210\/en.2013-1174","article-title":"Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma","volume":"154","author":"Shimamura","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2019.09.017_bib34","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1158\/2159-8290.CD-15-0330","article-title":"NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition","volume":"5","author":"Garcia-Rendueles","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2019.09.017_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/17460441.2016.1223036","article-title":"Mouse models of medullary thyroid cancer and developing new targeted therapies","volume":"11","author":"Paragliola","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.canlet.2019.09.017_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1210\/jc.2014-2803","article-title":"Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations","volume":"100","author":"Smith","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib37","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/mc.22887","article-title":"Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer","volume":"57","author":"Morton","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2019.09.017_bib38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib39","series-title":"Cancer: Principles and Practice of Oncology [11ed.]","author":"DeVita","year":"2018"},{"key":"10.1016\/j.canlet.2019.09.017_bib40","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK signaling pathways in cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2019.09.017_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2015.01.001","article-title":"Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers","volume":"4","author":"S\u00e9galiny","year":"2015","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib42","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fendo.2012.00054","article-title":"RET\/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma","volume":"3","author":"Romei","year":"2012","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.canlet.2019.09.017_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mce.2017.06.023","article-title":"Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia","volume":"460","author":"Bellelli","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/ERC-19-0011","article-title":"PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib46","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","article-title":"Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers","volume":"78","author":"Untch","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib47","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-10-2762","article-title":"Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model","volume":"17","author":"Gule","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib48","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-04-4196","article-title":"Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation","volume":"65","author":"Younes","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-04-0293","article-title":"Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788","volume":"4","author":"Kim","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ebiom.2016.09.007","article-title":"PDGFR\u03b1 regulates follicular cell differentiation driving treatment resistance and disease recurrence in papillary thyroid cancer","volume":"12","author":"Lopez-Campistrous","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2019.09.017_bib51","first-page":"235","article-title":"VEGF Trapon inhibits tumor growth in papillary thyroid carcinoma","volume":"19","author":"Peng","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12105-015-0619-z","article-title":"When thyroid carcinoma goes bad: a morphological and molecular analysis","volume":"9","author":"Papp","year":"2015","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.canlet.2019.09.017_bib53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib54","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/1535-7163.MCT-17-0559","article-title":"Anti-hTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft","volume":"17","author":"Lombardo","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib55","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/carcin\/bgp167","article-title":"Role of NKX2-1 in N-bis(2-hydroxypropyl)-nitrosamine-induced thyroid adenoma in mice","volume":"30","author":"Hoshi","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2019.09.017_bib56","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib57","doi-asserted-by":"crossref","first-page":"19843","DOI":"10.18632\/oncotarget.15773","article-title":"HER inhibitor promotes BRAF\/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib58","doi-asserted-by":"crossref","first-page":"11752","DOI":"10.18632\/oncotarget.2555","article-title":"BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications","volume":"5","author":"Oikonomou","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib59","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2019.09.017_bib60","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2019.09.017_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/thy.2018.0028","article-title":"Radioiodine uptake and thyroglobulin-guided radioiodine remnant ablation in patients with differentiated thyroid cancer: a prospective, randomized, open-label, controlled trial","volume":"29","author":"Jin","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib62","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2019.09.017_bib63","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1089\/thy.2009.0240","article-title":"Molecular diagnostics and predictors in thyroid cancer","volume":"19","author":"Nikiforova","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13578-018-0224-4","article-title":"INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression","volume":"8","author":"Guan","year":"2018","journal-title":"Cell Biosci."},{"key":"10.1016\/j.canlet.2019.09.017_bib65","doi-asserted-by":"crossref","first-page":"E1448","DOI":"10.3390\/ijms19051448","article-title":"mTOR pathway in papillary thyroid carcinoma: different contributions of mTORC1 and mTORC2 complexes for tumor behavior and SLC5A5 mRNA expression","volume":"19","author":"Tavares","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib66","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1158\/0008-5472.CAN-18-1954","article-title":"A nonpump function of sodium iodide symporter in thyroid cancer via cross-talk with PTEN signaling","volume":"78","author":"Feng","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib67","doi-asserted-by":"crossref","first-page":"18038","DOI":"10.18632\/oncotarget.3833","article-title":"Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis","volume":"6","author":"Sadowski","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib68","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"The Oncologist"},{"key":"10.1016\/j.canlet.2019.09.017_bib69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hed.23316","article-title":"Src inhibitors in suppression of papillary thyroid carcinoma growth","volume":"36","author":"Henderson","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.canlet.2019.09.017_bib70","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-11-2892","article-title":"SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer","volume":"18","author":"Kim","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib71","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1158\/1078-0432.CCR-11-3359","article-title":"Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis","volume":"18","author":"Chan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib72","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.18632\/oncotarget.2130","article-title":"Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer","volume":"5","author":"Vanden Borre","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2567.2005.02091.x","article-title":"Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas","volume":"114","author":"Mitchell","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2019.09.017_bib74","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK\u2013STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2019.09.017_bib75","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1210\/en.2013-1128","article-title":"Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model","volume":"154","author":"Kim","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2019.09.017_bib76","doi-asserted-by":"crossref","first-page":"E2361","DOI":"10.1073\/pnas.1201232109","article-title":"STAT3 negatively regulates thyroid tumorigenesis","volume":"109","author":"Couto","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.09.017_bib77","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers6010526","article-title":"The role of STAT3 in thyroid cancer","volume":"6","author":"Sosonkina","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2019.09.017_bib78","article-title":"Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.09.017_bib79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2119\/molmed.2011.00238","article-title":"c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death","volume":"18","author":"Bu","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib80","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/mc.22418","article-title":"c-Met-mediated reactivation of PI3K\/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition","volume":"55","author":"Byeon","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2019.09.017_bib81","first-page":"7521","article-title":"LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway","volume":"17","author":"Sui","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2019.09.017_bib82","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20728","article-title":"Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression","volume":"6","author":"Anelli","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.canlet.2019.09.017_bib83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.09.017_bib84","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nn.4620","article-title":"AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma","volume":"20","author":"Chow","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.canlet.2019.09.017_bib85","doi-asserted-by":"crossref","first-page":"9836256","DOI":"10.1155\/2018\/9836256","article-title":"Onco-multi-omics approach: a new frontier in cancer research","volume":"2018","author":"Chakraborty","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.canlet.2019.09.017_bib86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1101\/gr.124354.111","article-title":"Translating cancer \u201comics\u201d to improved outcomes","volume":"22","author":"Vucic","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib87","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib88","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib89","first-page":"710","article-title":"An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias","volume":"6","author":"Mirantes","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.canlet.2019.09.017_bib90","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/carcin\/bgq059","article-title":"Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer","volume":"31","author":"Guigon","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2019.09.017_bib91","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Lim","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib92","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.bjc.6602461","article-title":"Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines","volume":"92","author":"Nobuhara","year":"2005","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2019.09.017_bib93","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1158\/1078-0432.CCR-04-0690","article-title":"Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib94","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/thy.2011.0380","article-title":"Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in anaplastic thyroid carcinoma cells","volume":"22","author":"Kim","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib95","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00280-006-0185-x","article-title":"Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells","volume":"58","author":"Kurebayashi","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2019.09.017_bib96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer","volume":"18","author":"Pennell","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib97","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/ijc.32041","article-title":"Anti-PD-1\/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer","volume":"144","author":"Gunda","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib98","first-page":"2225","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2019.09.017_bib99","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib100","first-page":"181","article-title":"Anti-tumor activity of motesanib in a medullary thyroid cancer model","volume":"35","author":"Coxon","year":"2012","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.canlet.2019.09.017_bib101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib102","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00432-013-1465-6","article-title":"Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer","volume":"139","author":"Chan","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib103","doi-asserted-by":"crossref","first-page":"E936","DOI":"10.1210\/jc.2013-2658","article-title":"Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors","volume":"99","author":"Isham","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib104","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib105","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib106","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2013-3713","article-title":"Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H","volume":"99","author":"Bible","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib107","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib108","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1210\/jc.2010-1071","article-title":"Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E","volume":"96","author":"Lee","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib109","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2019.09.017_bib110","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/1078-0432.CCR-15-2792","article-title":"Sorafenib and quinacrine target anti-apoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer (ATC)","volume":"22","author":"Abdulghani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib111","first-page":"711","article-title":"Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer","volume":"39","author":"Yi","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2019.09.017_bib112","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.2147\/IJN.S187240","article-title":"Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy","volume":"13","author":"Ke","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2019.09.017_bib113","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1158\/1535-7163.MCT-06-0595","article-title":"Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice","volume":"6","author":"Kim","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib114","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-07-1772","article-title":"Sorafenib potently inhibits papillary thyroid carcinomas harboring RET\/PTC1 rearrangement","volume":"14","author":"Henderson","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/1535-7163.MCT-09-0694","article-title":"Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma","volume":"9","author":"Alfano","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"DECISION investigators, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2019.09.017_bib117","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.biopha.2017.01.135","article-title":"Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells","volume":"88","author":"Wang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2019.09.017_bib118","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-10-2041","article-title":"Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models","volume":"17","author":"Broutin","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib119","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/cbt.12.5.16303","article-title":"Sunitinib inhibits papillary thyroid carcinoma with RET\/PTC rearrangement but not BRAF mutation","volume":"12","author":"Jeong","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib120","doi-asserted-by":"crossref","first-page":"E1465","DOI":"10.1210\/jc.2013-1364","article-title":"Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1\/2 phosphorylation and by down-regulation of cyclin-D1","volume":"98","author":"Di Desidero","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib121","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2013-2574","article-title":"Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer","volume":"99","author":"Lopergolo","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib122","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib123","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1530\/EJE-15-0930","article-title":"Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer","volume":"174","author":"Bikas","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib124","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1210\/jc.2012-3671","article-title":"Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo","volume":"98","author":"Starenki","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib125","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1002\/jcb.26620","article-title":"Signaling cascades in thyroid cancer: increasing the armory of archers to hit bullseye","volume":"119","author":"Rashid","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2019.09.017_bib126","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2967\/jnumed.110.081745","article-title":"Metabolic imaging allows early prediction of response to vandetanib","volume":"52","author":"Walter","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib127","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2013.07.006","article-title":"Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice","volume":"339","author":"Starenki","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.09.017_bib128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2013.0514","article-title":"Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array","volume":"24","author":"Broutin","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib129","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1038\/onc.2014.392","article-title":"Mortalin (GRP75\/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells","volume":"34","author":"Starenki","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.09.017_bib130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/15384047.2017.1323594","article-title":"Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells","volume":"18","author":"Starenki","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib131","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib132","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib133","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1210\/jc.2016-1999","article-title":"Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib","volume":"102","author":"Wang","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib134","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.12659\/MSM.910084","article-title":"The MEK1\/2 inhibitor AZD6244 sensitizes BRAF-mutant thyroid cancer to vemurafenib","volume":"24","author":"Song","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.canlet.2019.09.017_bib135","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3892\/or.2016.4918","article-title":"Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib","volume":"36","author":"Wei","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2019.09.017_bib136","doi-asserted-by":"crossref","first-page":"dju182","DOI":"10.1093\/jnci\/dju182","article-title":"Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment","volume":"106","author":"Sadow","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2019.09.017_bib137","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/ERC-17-0182","article-title":"Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo","volume":"25","author":"Tsumagari","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib138","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2015.12.016","article-title":"Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL","volume":"372","author":"Cha","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.09.017_bib139","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2019.09.017_bib140","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1210\/en.2003-1258","article-title":"Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium\/iodide symporter thyroperoxidase and thyroglobulin","volume":"145","author":"Furuya","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2019.09.017_bib141","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.1158\/1078-0432.CCR-05-0455","article-title":"Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma","volume":"11","author":"Bravo","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.6059","article-title":"Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma","volume":"27","author":"Sherman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib143","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/aps.2017.107","article-title":"Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer","volume":"38","author":"Xie","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2019.09.017_bib144","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1159\/000485583","article-title":"Apatinib inhibits angiogenesis via suppressing akt\/GSK3\u03b2\/ANG signaling pathway in anaplastic thyroid cancer","volume":"44","author":"Jin","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.canlet.2019.09.017_bib145","doi-asserted-by":"crossref","first-page":"37662","DOI":"10.18632\/oncotarget.26480","article-title":"Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer","volume":"9","author":"Pozo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib146","doi-asserted-by":"crossref","first-page":"E811","DOI":"10.1210\/jc.2012-2672","article-title":"Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer","volume":"98","author":"De Falco","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib147","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.04.019","article-title":"Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias","volume":"63","author":"Mirantes","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib148","doi-asserted-by":"crossref","first-page":"35946","DOI":"10.18632\/oncotarget.16412","article-title":"Multiple anti-tumor effects of Reparixin on thyroid cancer","volume":"8","author":"Liotti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib149","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1210\/en.2008-0279","article-title":"Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells","volume":"149","author":"Meng","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2019.09.017_bib150","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-04-0463","article-title":"Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin","volume":"10","author":"V Starenki","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib151","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1124\/mol.108.052605","article-title":"A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway","volume":"75","author":"Zhu","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2019.09.017_bib152","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vph.2009.10.006","article-title":"Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells","volume":"52","author":"Zhu","year":"2010","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.canlet.2019.09.017_bib153","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.2147\/IJN.S137335","article-title":"Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles","volume":"12","author":"Li","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2019.09.017_bib154","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/thy.2013.0277","article-title":"In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset","volume":"24","author":"Kucerova","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.111.188730","article-title":"Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells","volume":"341","author":"Tseng","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib156","doi-asserted-by":"crossref","first-page":"34832","DOI":"10.18632\/oncotarget.8989","article-title":"Metformin blocks progression of obesity-activated thyroid cancer in a mouse model","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib157","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1530\/ERC-18-0071","article-title":"Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer","volume":"25","author":"Park","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib158","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JME-16-0134","article-title":"Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo","volume":"58","author":"Shen","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib159","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1677\/joe.0.1790387","article-title":"Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line","volume":"179","author":"Chang","year":"2003","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-15-0417","article-title":"Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model","volume":"23","author":"Park","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib161","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-06-0793","article-title":"Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer","volume":"12","author":"Younes","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib162","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046869","article-title":"AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines","volume":"7","author":"Couto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.09.017_bib163","doi-asserted-by":"crossref","first-page":"16517","DOI":"10.18632\/oncotarget.7760","article-title":"Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib164","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.18632\/oncotarget.3268","article-title":"Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/1078-0432.1336.11.3","article-title":"Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth","volume":"11","author":"Ezzat","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib166","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1210\/en.2004-1134","article-title":"Fibroblast growth factor receptors as molecular targets in thyroid carcinoma","volume":"146","author":"St Bernard","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2019.09.017_bib167","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1007\/s11095-012-0727-3","article-title":"Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells","volume":"29","author":"Hua","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib168","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2009-1926","article-title":"Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid","volume":"95","author":"Yalcin","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib169","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7150\/thno.17322","article-title":"Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer","volume":"7","author":"Wei","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2019.09.017_bib170","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/ERC-14-0268","article-title":"Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression","volume":"21","author":"Champa","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib171","doi-asserted-by":"crossref","first-page":"34453","DOI":"10.18632\/oncotarget.9121","article-title":"Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis","volume":"7","author":"Champa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib172","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.1210\/jc.2013-2321","article-title":"CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"99","author":"Antonelli","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib173","doi-asserted-by":"crossref","first-page":"E288","DOI":"10.1210\/jc.2010-1905","article-title":"Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer","volume":"96","author":"Antonelli","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib174","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.surg.2010.09.026","article-title":"A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo","volume":"148","author":"Samadi","year":"2010","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2019.09.017_bib175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjsurg.2012.07.027","article-title":"A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers","volume":"204","author":"Cohen","year":"2012","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.canlet.2019.09.017_bib176","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/mmr.2012.1166","article-title":"Antitumor activity of Pulsatilla koreana extract in anaplastic thyroid cancer via apoptosis and anti-angiogenesis","volume":"7","author":"Park","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2019.09.017_bib177","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-13-0187","article-title":"Off-target effects of c-MET inhibitors on thyroid cancer cells","volume":"13","author":"Zhou","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib178","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.09.017_bib179","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/ERC-14-0510","article-title":"Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer","volume":"22","author":"Mehta","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2010-0317","article-title":"Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer","volume":"16","author":"Nucera","year":"2011","journal-title":"The Oncologist"},{"key":"10.1016\/j.canlet.2019.09.017_bib181","doi-asserted-by":"crossref","first-page":"E1600","DOI":"10.1073\/pnas.1404357111","article-title":"p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer","volume":"111","author":"McFadden","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.09.017_bib182","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1038\/cddis.2014.78","article-title":"Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K\/AKT pathways","volume":"5","author":"Gunda","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2019.09.017_bib183","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","article-title":"Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer","volume":"119","author":"Gunda","year":"2018","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2019.09.017_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.02.028","article-title":"Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis","volume":"395","author":"Gunda","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.09.017_bib185","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/onc.2015.253","article-title":"TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer","volume":"35","author":"Zou","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.09.017_bib186","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/en.2011-1519","article-title":"Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer","volume":"153","author":"Nehs","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2019.09.017_bib187","doi-asserted-by":"crossref","first-page":"10649","DOI":"10.1073\/pnas.1004934107","article-title":"B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression","volume":"107","author":"Nucera","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.09.017_bib188","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1158\/0008-5472.CAN-16-2066","article-title":"Cyp24a1 attenuation limits progression of braf(V600E) -induced papillary thyroid cancer cells and sensitizes them to BRAF(V600E) inhibitor PLX4720","volume":"77","author":"Zou","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib189","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2009-0373","article-title":"Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells","volume":"95","author":"Salerno","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib190","first-page":"2170","article-title":"Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells","volume":"86","author":"Ohta","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib191","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/sj.onc.1209299","article-title":"PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway","volume":"25","author":"Kato","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.09.017_bib192","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1038\/s41388-018-0274-4","article-title":"A modified gene trap approach for improved high-throughput cancer drug discovery","volume":"37","author":"Morris","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.09.017_bib193","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mce.2012.01.015","article-title":"Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line","volume":"355","author":"Vivaldi","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib194","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/thy.2008.0194","article-title":"Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice","volume":"19","author":"Quidville","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib195","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1677\/joe.1.06490","article-title":"Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line","volume":"190","author":"Wang","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib196","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1124\/jpet.109.152447","article-title":"Clodronate-induced cell apoptosis in human thyroid carcinoma is mediated via the P2 receptor signaling pathway","volume":"330","author":"Yang","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib197","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cncr.24792","article-title":"Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma","volume":"116","author":"Salaun","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib198","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12020-012-9665-4","article-title":"Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer","volume":"42","author":"Wunderlich","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.canlet.2019.09.017_bib199","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1349-7006.2011.01853.x","article-title":"Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer","volume":"102","author":"Wunderlich","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib200","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/1535-7163.MCT-10-0062","article-title":"MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo","volume":"9","author":"Henderson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib201","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1089\/thy.2013.0037","article-title":"The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations","volume":"23","author":"Russo","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib202","doi-asserted-by":"crossref","first-page":"19948","DOI":"10.18632\/oncotarget.7890","article-title":"High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1349-7006.2011.02128.x","article-title":"Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts","volume":"103","author":"Iwase","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib204","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1535-7163.MCT-10-0262","article-title":"Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas","volume":"9","author":"Levy","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib205","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1210\/jc.2011-1506","article-title":"FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma","volume":"97","author":"Ahmed","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib206","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1349-7006.2011.02181.x","article-title":"HIF-1alpha and HSP90: target molecules selected from a tumorigenic papillary thyroid carcinoma cell line","volume":"103","author":"Mo","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib207","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/carcin\/bgu051","article-title":"High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma","volume":"35","author":"Ahmed","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2019.09.017_bib208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054302","article-title":"Genetic and pharmacological targeting of CSF-1\/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression","volume":"8","author":"Ryder","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.09.017_bib209","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","article-title":"Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases","volume":"23","author":"Kotian","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.freeradbiomed.2013.10.818","article-title":"Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation","volume":"67","author":"Chang","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.canlet.2019.09.017_bib211","doi-asserted-by":"crossref","first-page":"8659","DOI":"10.1007\/s13277-014-2118-3","article-title":"PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration","volume":"35","author":"Che","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.canlet.2019.09.017_bib212","doi-asserted-by":"crossref","first-page":"E1934","DOI":"10.1210\/jc.2011-1426","article-title":"GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways","volume":"96","author":"Burrows","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib213","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.radonc.2013.06.027","article-title":"Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity","volume":"108","author":"Burrows","year":"2013","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib214","article-title":"A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.09.017_bib215","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/carcin\/bgm174","article-title":"Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer","volume":"28","author":"Furuya","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2019.09.017_bib216","doi-asserted-by":"crossref","first-page":"E974","DOI":"10.1210\/jc.2014-4356","article-title":"Role of X-linked inhibitor of apoptosis as a prognostic marker and therapeutic target in papillary thyroid carcinoma","volume":"100","author":"Hussain","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib217","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1002\/jcb.26604","article-title":"PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo","volume":"119","author":"Jiang","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2019.09.017_bib218","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsbmb.2011.04.009","article-title":"Anti-thyroid cancer properties of a novel isoflavone derivative, 7-(O)-carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine in vitro and in vivo","volume":"126","author":"Somjen","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2019.09.017_bib219","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1158\/0008-5472.CAN-09-1077","article-title":"Genetic alterations in the phosphoinositide 3-kinase\/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib220","first-page":"2049","article-title":"Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer","volume":"35","author":"Cha","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib221","doi-asserted-by":"crossref","first-page":"41294","DOI":"10.18632\/oncotarget.17180","article-title":"Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib222","doi-asserted-by":"crossref","first-page":"E1976","DOI":"10.1210\/jc.2013-3976","article-title":"Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines","volume":"99","author":"Malaguarnera","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib223","doi-asserted-by":"crossref","first-page":"11383","DOI":"10.1038\/s41598-017-11426-3","article-title":"Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma","volume":"7","author":"Werner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2019.09.017_bib224","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-14-3251","article-title":"Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer","volume":"21","author":"Mehta","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib225","doi-asserted-by":"crossref","first-page":"6878","DOI":"10.18632\/oncotarget.6901","article-title":"Targeted near infrared hyperthermia combined with immune stimulation for optimized therapeutic efficacy in thyroid cancer treatment","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib226","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1186\/s12885-015-1982-6","article-title":"Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2019.09.017_bib227","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neo.2017.12.003","article-title":"Anti-cancer effects of HNHA and lenvatinib by the suppression of EMT-mediated drug resistance in cancer stem cells","volume":"20","author":"Lee","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2019.09.017_bib228","article-title":"Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.09.017_bib229","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1541-7786.MCR-16-0007","article-title":"FAK expression, not kinase activity, is a Key mediator of thyroid tumorigenesis and protumorigenic processes","volume":"14","author":"Kessler","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/ERC-16-0103","article-title":"SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model","volume":"23","author":"Zhu","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib231","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/1078-0432.CCR-16-0914","article-title":"Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model","volume":"23","author":"Zhu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib232","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2015.12.008","article-title":"Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer","volume":"469","author":"Gao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2019.09.017_bib233","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e17025","article-title":"Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: a Wisconsin Oncology Network trial","volume":"31","author":"Traynor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib234","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/cgt.2012.47","article-title":"Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy","volume":"19","author":"V Reddi","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib235","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.lfs.2012.09.026","article-title":"Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of 131I on the in vivo management of differentiated thyroid cancer","volume":"91","author":"Meng","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib236","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/1535-7163.MCT-15-0702","article-title":"The mitogen-activated protein kinase pathway facilitates resistance to the src inhibitor dasatinib in thyroid cancer","volume":"15","author":"Beadnell","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib237","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1210\/jc.2017-02178","article-title":"Downregulation of SKP2 in papillary thyroid cancer acts synergistically with TRAIL on inducing apoptosis via ROS","volume":"103","author":"Pratheeshkumar","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.09.017_bib238","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.amjms.2017.03.025","article-title":"Antiviral drug ribavirin targets thyroid cancer cells by inhibiting the eIF4E-beta-catenin axis","volume":"354","author":"Shen","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib239","doi-asserted-by":"crossref","first-page":"17194","DOI":"10.18632\/oncotarget.7839","article-title":"Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer","volume":"7","author":"Brauner","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.09.017_bib240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molonc.2014.07.022","article-title":"PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma","volume":"9","author":"Passaro","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib241","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.surg.2010.09.001","article-title":"Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer","volume":"148","author":"Nehs","year":"2010","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2019.09.017_bib242","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/erc.0.0080219","article-title":"Discovery of a novel Raf kinase inhibitor","volume":"8","author":"Lyons","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib243","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.1.05895","article-title":"How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy","volume":"183","author":"Fagin","year":"2004","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib244","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-05-2378","article-title":"BRAF is a therapeutic target in aggressive thyroid carcinoma","volume":"12","author":"Salvatore","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.09.017_bib245","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-07-2422","article-title":"Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib\/tipifarnib","volume":"7","author":"Hong","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.09.017_bib246","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1349-7006.2008.00882.x","article-title":"Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo","volume":"99","author":"Stenner","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2019.09.017_bib247","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib248","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer","volume":"27","author":"Kloos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib249","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.09.017_bib250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-11-0129","article-title":"Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population","volume":"165","author":"Ahmed","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.09.017_bib251","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib253","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12020-014-0481-x","article-title":"Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center","volume":"49","author":"Gallo","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.canlet.2019.09.017_bib254","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1002\/cncr.30861","article-title":"Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer","volume":"123","author":"Sherman","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/ERC-17-0016","article-title":"Timing of multikinase inhibitor initiation in differentiated thyroid cancer","volume":"24","author":"Brose","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib256","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/ERC-18-0150","article-title":"Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer","volume":"25","author":"Lin","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.09.017_bib257","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.2147\/IJN.S187240","article-title":"Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy","volume":"13","author":"Ke","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2019.09.017_bib258","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/thy.2017.0356","article-title":"Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study","volume":"28","author":"Kim","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2019.09.017_bib259","article-title":"Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial","author":"Capdevila","year":"2019","journal-title":"Mol. Cancer Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519304896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519304896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:45:24Z","timestamp":1759592724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519304896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":258,"alternative-id":["S0304383519304896"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.09.017","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}